Haider J Warraich1, Jamal S Rana2,3. 1. Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC, USA. 2. Division of Cardiology, Kaiser Permanente Medical Center, 3600 Broadway, Oakland, CA, 94611, USA. jamal.s.rana@kp.org. 3. Department of Medicine, University of California San Francisco, San Francisco, CA, USA. jamal.s.rana@kp.org.
Abstract
PURPOSE OF REVIEW: Dyslipidemia in patients with T2DM confers significant additional risk of adverse outcomes to patients with cardiovascular disease (CVD). These patients carry residual risk of adverse outcomes despite optimal management with conventional therapy such as lifestyle changes and statin therapy. The role of both nonstatin monotherapy in statin-intolerant patients and combination therapy with statins in patients with high risk of CVD events has been well studied. We sought to review the role of newer therapies in risk reduction in these patients. RECENT FINDINGS: Traditionally, non-statin options have included medications such as niacin, ezetimibe, fenofibrate, and n-3 fatty acids. Recently, drugs such as ezetimibe, inclisiran, and PCSK9 inhibitors have been studied with favorable results without an increased risk of developing new-onset diabetes. These medications hold the promise of increasing options to reduce cardiovascular risk in patients with T2DM. The role of newer non-statin therapies in patients with diabetic dyslipidemia in combination with statins needs to be further explored.
PURPOSE OF REVIEW: Dyslipidemia in patients with T2DM confers significant additional risk of adverse outcomes to patients with cardiovascular disease (CVD). These patients carry residual risk of adverse outcomes despite optimal management with conventional therapy such as lifestyle changes and statin therapy. The role of both nonstatin monotherapy in statin-intolerant patients and combination therapy with statins in patients with high risk of CVD events has been well studied. We sought to review the role of newer therapies in risk reduction in these patients. RECENT FINDINGS: Traditionally, non-statin options have included medications such as niacin, ezetimibe, fenofibrate, and n-3 fatty acids. Recently, drugs such as ezetimibe, inclisiran, and PCSK9 inhibitors have been studied with favorable results without an increased risk of developing new-onset diabetes. These medications hold the promise of increasing options to reduce cardiovascular risk in patients with T2DM. The role of newer non-statin therapies in patients with diabetic dyslipidemia in combination with statins needs to be further explored.
Entities:
Keywords:
Alirocumab; Dyslipidemia; Evolocumab; Ezetimibe; Fibrates; Fish oil; Inclisiran; PCSK9 inhibitors; Statins; Type 2 diabetes mellitus
Authors: Ulf Landmesser; M. John Chapman; Michel Farnier; Baris Gencer; Stephan Gielen; G Kees Hovingh; Thomas F Lüscher; David Sinning; Lale Tokgözoglu; Olov Wiklund; Jose Luis Zamorano; Fausto J Pinto; Alberico L Catapano Journal: Eur Heart J Date: 2017-08-01 Impact factor: 29.983
Authors: Donald M Lloyd-Jones; Pamela B Morris; Christie M Ballantyne; Kim K Birtcher; David D Daly; Sondra M DePalma; Margo B Minissian; Carl E Orringer; Sidney C Smith Journal: J Am Coll Cardiol Date: 2016-04-01 Impact factor: 24.094
Authors: Gualberto Ruaño; Richard L Seip; Andreas Windemuth; Stefan Zöllner; Gregory J Tsongalis; Jose Ordovas; James Otvos; Cherie Bilbie; Mary Miles; Robert Zoeller; Paul Visich; Paul Gordon; Theodore J Angelopoulos; Linda Pescatello; Niall Moyna; Paul D Thompson Journal: Atherosclerosis Date: 2005-07-07 Impact factor: 5.162
Authors: Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski Journal: N Engl J Med Date: 2013-06-24 Impact factor: 91.245
Authors: William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub Journal: N Engl J Med Date: 2011-11-15 Impact factor: 91.245
Authors: Min Jun; Celine Foote; Jicheng Lv; Bruce Neal; Anushka Patel; Stephen J Nicholls; Diederick E Grobbee; Alan Cass; John Chalmers; Vlado Perkovic Journal: Lancet Date: 2010-05-10 Impact factor: 79.321
Authors: Ronald J Sigal; Glen P Kenny; Normand G Boulé; George A Wells; Denis Prud'homme; Michelle Fortier; Robert D Reid; Heather Tulloch; Douglas Coyle; Penny Phillips; Alison Jennings; James Jaffey Journal: Ann Intern Med Date: 2007-09-18 Impact factor: 25.391
Authors: Theingi Aung; Jim Halsey; Daan Kromhout; Hertzel C Gerstein; Roberto Marchioli; Luigi Tavazzi; Johanna M Geleijnse; Bernhard Rauch; Andrew Ness; Pilar Galan; Emily Y Chew; Jackie Bosch; Rory Collins; Sarah Lewington; Jane Armitage; Robert Clarke Journal: JAMA Cardiol Date: 2018-03-01 Impact factor: 14.676
Authors: Kausik K Ray; Lawrence A Leiter; Dirk Müller-Wieland; Bertrand Cariou; Helen M Colhoun; Robert R Henry; Francisco J Tinahones; Maja Bujas-Bobanovic; Catherine Domenger; Alexia Letierce; Rita Samuel; Stefano Del Prato Journal: Diabetes Obes Metab Date: 2018-03-23 Impact factor: 6.577
Authors: Juan R Ulloque-Badaracco; Melany D Mosquera-Rojas; Enrique A Hernandez-Bustamante; Esteban A Alarcón-Braga; Ricardo R Ulloque-Badaracco; Ali Al-Kassab-Córdova; Percy Herrera-Añazco; Vicente A Benites-Zapata; Adrian V Hernandez Journal: Int J Clin Pract Date: 2022-08-10 Impact factor: 3.149